MARKET

AKTS

AKTS

AKTIS ONCOLOGY INC
NASDAQ
19.43
-0.20
-1.02%
After Hours: 19.43 0 0.00% 19:30 09/25 EDT
OPEN
19.71
PREV CLOSE
19.63
HIGH
19.81
LOW
18.97
VOLUME
518.91K
TURNOVER
--
52 WEEK HIGH
34.19
52 WEEK LOW
14.72
MARKET CAP
1.04B
P/E (TTM)
-17.4683
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AKTS last week (0914-0918)?
Weekly Report · 5d ago
Weekly Report: what happened at AKTS last week (0907-0911)?
Weekly Report · 09/14 10:35
Aktis Oncology Price Target Announced at $40.00/Share by Oppenheimer
Dow Jones · 09/09 14:46
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40
Benzinga · 09/09 14:37
Aktis Oncology initiated with an Outperform at Oppenheimer
TipRanks · 09/09 10:10
Weekly Report: what happened at AKTS last week (0831-0904)?
Weekly Report · 09/07 10:28
Weekly Report: what happened at AKTS last week (0824-0828)?
Weekly Report · 08/31 10:36
Weekly Report: what happened at AKTS last week (0817-0821)?
Weekly Report · 08/24 10:37
More
About AKTS
Aktis Oncology, Inc. is a clinical-stage oncology company. The Company is focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The Company’s proprietary mini-protein radio conjugate platform aims to safely confer efficacy to a range of patient populations. Its mini-protein radio conjugates are designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors with high tumor penetration and prolonged retention, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Its pipeline includes AKY-1189 and AKY-2519. AKY-1189, is targeting Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, colorectal cancer and cervical cancer. AKY-2519 targets B7-H3 expressing solid tumors, such as prostate, lung and breast cancers.

Webull offers Aktis Oncology, Inc. stock information, including NASDAQ: AKTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTS stock methods without spending real money on the virtual paper trading platform.